Camrelizumab | Interleukin Related interleukin-related.com

Product Name :
Camrelizumab

Search keywords :
Camrelizumab

drugId :
null

Target Vo:
Programmed cell death protein 1

Target Vo Short Name :
PD-1

Moa_Name:
Antibody-dependent cell-mediated cytotoxicity (ADCC) effects

First Approval Country :
Mainland China

First Approval Date Filter:
2019

Origin Company_Name :
Jiangsu Hengrui Medicine Co Ltd

Active Company_Name :
Atridia Pty Ltd

Active Indication_Name:
Nasopharyngeal Carcinoma

In Active Indication_Name:
Respiratory Tract Diseases

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
p21 Antibody
CD11b Antibody
SP1 Antibody: SP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 81 kDa, targeting to SP1. It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts